Vivani Medical, Inc.
Vivani Medical, Inc. is a U.S.-based biopharmaceutical company focused on miniature, ultra long-acting drug implant programs and related delivery platforms. The company also holds neuromodulation assets through its subsidiary Cortigent, which was formed from legacy Second Sight Medical Products and is being positioned as a separate business.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenuePreclinical and clinical-stage miniature implants designed to deliver GLP-1 therapies over long durations.
Implant-based therapies aimed at obesity, overweight, and type 2 diabetes indications.
Brain implant and neuromodulation assets intended to help patients recover critical body functions.
Customers
Vivani does not sell commercial products broadly today; its direct counterparties are primarily clinical investigators, research partners, regulators, and contract development and manufacturing organizations that support product development. The eventual end customers for its implant programs are patients with chronic metabolic diseases, while Cortigent’s technologies are aimed at patients with severe neurological impairment or loss of function.
CROs, trial sites, and manufacturers that support preclinical and clinical testing of implant candidates.
People with obesity, overweight, or type 2 diabetes who are the intended users of GLP-1 implant therapies.
Patients with severe neurological conditions who may benefit from Cortigent's implantable systems.
FDA and other regulators that determine whether programs can advance into and through clinical development.
Strategy
Vivani's strategy centers on advancing its miniature drug implant platform, with NPM-115, NPM-119, and NPM-139 representing the core metabolic pipeline. In parallel, the company is working to separate Cortigent into an independent public company so each business can pursue its own therapeutic focus and capital strategy.
Clinical progress is the main value driver for a development-stage company.
A spin-off can create two more focused businesses with distinct capital needs and strategies.
A platform approach can extend the technology beyond a single lead asset.
Geography
Vivani is headquartered in the United States and operates as a development-stage company with U.S.-based corporate and regulatory activity. It also established Vivani Medical Australia Pty Ltd. to support studies of its product candidates, reflecting a small but important international clinical footprint.
Risks
Vivani faces the typical risks of a development-stage biotech company: heavy dependence on external financing, uncertain clinical outcomes, and regulatory delays. Its dual-track structure also adds execution risk because the company must advance metabolic implants while managing the separation of Cortigent and the associated legal, tax, and listing approvals.
- Additional financing requirementImpact: HighLikelihood: High
Development programs consume cash before any product revenue exists, so funding access is critical.
Exposure: Company-wide development operations
- Clinical development uncertaintyImpact: HighLikelihood: Medium
Preclinical and clinical programs can fail on safety, efficacy, or pharmacokinetics.
Exposure - Regulatory delay or holdImpact: HighLikelihood: Medium
FDA or other regulators can pause, narrow, or delay studies and commercialization.
Exposure: Clinical-stage implant programs
- Third-party dependenceImpact: MediumLikelihood: Medium
CROs, manufacturers, and study sites affect trial quality, timing, and cost.
Exposure: Clinical and preclinical operations
- Cortigent spin-off executionImpact: MediumLikelihood: Low
The separation requires SEC, Nasdaq, tax, and board approvals and could be delayed or fail.
Exposure: Cortigent neuromodulation business
Accounting
Judgemental itemsMost spending is expensed as incurred, so trial timing directly affects reported results.
Impact: Clinical progress changes quarterly expense levels
Non-cash awards affect operating expense and require valuation assumptions.
Impact: Can materially affect G&A and R&D expense
NIH or similar grants may be recorded as reductions to operating expense.
Impact: Offsets development spend and affects comparability
Cortigent remains consolidated until separation, which affects assets, liabilities, and disclosures.
Impact: Spin-off timing can change reported structure and balances
Similar listed companies
Publicly listed companies with a comparable business focus.
Glucotrack, Inc.
GCTK · Surgical & Medical Instruments & Apparatus
NovaBridge Biosciences
NBP · Pharmaceutical Preparations
NovaBridge Biosciences is a global biotechnology company focused on discovering, developing, and partnering around differentiated therapeutic candidates in oncology and ophthalmology.
Corvex, Inc.
MOVE · Services-Computer Processing & Data Preparation
Skye Bioscience, Inc.
SKYE · Pharmaceutical Preparations
LivaNova PLC
LIVN · Electromedical & Electrotherapeutic Apparatus
LivaNova PLC is a medical technology company focused on therapies for cardiac and neurological conditions.
Ventyx Biosciences, Inc.
Pharmaceutical Preparations
Last updated: 24/09/2026